Annual Short Term Debt
$10.85 M
+$5.94 M+120.97%
31 December 2023
Summary:
Revance Therapeutics annual short term debt is currently $10.85 million, with the most recent change of +$5.94 million (+120.97%) on 31 December 2023. During the last 3 years, it has risen by +$6.11 million (+128.70%). RVNC annual short term debt is now -88.63% below its all-time high of $95.45 million, reached on 31 December 2012.RVNC Short Term Debt Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Short Term Debt
$27.36 M
-$4.25 M-13.44%
30 September 2024
Summary:
Revance Therapeutics quarterly short term debt is currently $27.36 million, with the most recent change of -$4.25 million (-13.44%) on 30 September 2024. Over the past year, it has increased by +$16.51 million (+152.10%). RVNC quarterly short term debt is now -71.33% below its all-time high of $95.45 million, reached on 31 December 2012.RVNC Quarterly Short Term Debt Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
RVNC Short Term Debt Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | - | +152.1% |
| 3 y3 years | +128.7% | +476.6% |
| 5 y5 years | +212.8% | +688.6% |
RVNC Short Term Debt High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | at high | +128.7% | -13.4% | +476.6% |
| 5 y | 5 years | at high | +212.8% | -13.4% | +688.6% |
| alltime | all time | -88.6% | -71.3% |
Revance Therapeutics Short Term Debt History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $27.36 M(-13.4%) |
| June 2024 | - | $31.61 M(+160.7%) |
| Mar 2024 | - | $12.13 M(+11.7%) |
| Dec 2023 | $10.85 M(+121.0%) | $10.85 M(-41.4%) |
| Sept 2023 | - | $18.52 M(-10.8%) |
| June 2023 | - | $20.77 M(-10.1%) |
| Mar 2023 | - | $23.09 M(+370.0%) |
| Dec 2022 | $4.91 M(+3.5%) | $4.91 M(-63.6%) |
| Sept 2022 | - | $13.50 M(-40.5%) |
| June 2022 | - | $22.70 M(-4.2%) |
| Mar 2022 | - | $23.69 M(+399.1%) |
| Dec 2021 | $4.75 M(+7.0%) | $4.75 M(-1.7%) |
| Sept 2021 | - | $4.83 M(-14.5%) |
| June 2021 | - | $5.65 M(+26.3%) |
| Mar 2021 | - | $4.47 M(+0.8%) |
| Dec 2020 | $4.44 M(+27.9%) | $4.44 M(+9.8%) |
| Sept 2020 | - | $4.04 M(+6.6%) |
| June 2020 | - | $3.79 M(+4.5%) |
| Mar 2020 | - | $3.63 M(+4.5%) |
| Dec 2019 | $3.47 M(>+9900.0%) | $3.47 M(+4.6%) |
| Sept 2019 | - | $3.32 M(+4.7%) |
| June 2019 | - | $3.17 M(+5.3%) |
| Mar 2019 | - | $3.01 M(>+9900.0%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2018 | $0.00(-100.0%) | $0.00(0.0%) |
| Sept 2018 | - | $0.00(0.0%) |
| June 2018 | - | $0.00(-100.0%) |
| Mar 2018 | - | $983.00 K(-47.5%) |
| Dec 2017 | $1.87 M(-46.1%) | $1.87 M(-31.4%) |
| Sept 2017 | - | $2.73 M(-23.2%) |
| June 2017 | - | $3.55 M(+1.4%) |
| Mar 2017 | - | $3.50 M(+0.8%) |
| Dec 2016 | $3.48 M(+10.8%) | $3.48 M(+4.1%) |
| Sept 2016 | - | $3.34 M(+0.8%) |
| June 2016 | - | $3.31 M(+1.8%) |
| Mar 2016 | - | $3.26 M(+3.9%) |
| Dec 2015 | $3.13 M(+6.6%) | $3.13 M(+3.9%) |
| Sept 2015 | - | $3.02 M(+3.9%) |
| June 2015 | - | $2.91 M(+811.0%) |
| Mar 2015 | - | $319.00 K(-89.2%) |
| Dec 2014 | $2.94 M(-87.1%) | $2.94 M(-66.4%) |
| Sept 2014 | - | $8.76 M(-20.7%) |
| June 2014 | - | $11.04 M(-17.6%) |
| Mar 2014 | - | $13.40 M(-41.4%) |
| Dec 2013 | $22.86 M(-76.1%) | $22.86 M(+176.4%) |
| Sept 2013 | - | $8.27 M(-91.3%) |
| Dec 2012 | $95.45 M(+1997.3%) | $95.45 M |
| Dec 2011 | $4.55 M | - |
FAQ
- What is Revance Therapeutics annual short term debt?
- What is the all time high annual short term debt for Revance Therapeutics?
- What is Revance Therapeutics quarterly short term debt?
- What is the all time high quarterly short term debt for Revance Therapeutics?
- What is Revance Therapeutics quarterly short term debt year-on-year change?
What is Revance Therapeutics annual short term debt?
The current annual short term debt of RVNC is $10.85 M
What is the all time high annual short term debt for Revance Therapeutics?
Revance Therapeutics all-time high annual short term debt is $95.45 M
What is Revance Therapeutics quarterly short term debt?
The current quarterly short term debt of RVNC is $27.36 M
What is the all time high quarterly short term debt for Revance Therapeutics?
Revance Therapeutics all-time high quarterly short term debt is $95.45 M
What is Revance Therapeutics quarterly short term debt year-on-year change?
Over the past year, RVNC quarterly short term debt has changed by +$16.51 M (+152.10%)